These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 8308774)
1. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. Clements PJ; Lachenbruch PA; Seibold JR; Zee B; Steen VD; Brennan P; Silman AJ; Allegar N; Varga J; Massa M J Rheumatol; 1993 Nov; 20(11):1892-6. PubMed ID: 8308774 [TBL] [Abstract][Full Text] [Related]
2. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. Clements P; Lachenbruch P; Siebold J; White B; Weiner S; Martin R; Weinstein A; Weisman M; Mayes M; Collier D J Rheumatol; 1995 Jul; 22(7):1281-5. PubMed ID: 7562759 [TBL] [Abstract][Full Text] [Related]
3. Durometry for the assessment of skin disease in systemic sclerosis. Kissin EY; Schiller AM; Gelbard RB; Anderson JJ; Falanga V; Simms RW; Korn JH; Merkel PA Arthritis Rheum; 2006 Aug; 55(4):603-9. PubMed ID: 16874783 [TBL] [Abstract][Full Text] [Related]
4. Variability of skin scores and clinical measurements in scleroderma. Pope JE; Baron M; Bellamy N; Campbell J; Carette S; Chalmers I; Dales P; Hanly J; Kaminska EA; Lee P J Rheumatol; 1995 Jul; 22(7):1271-6. PubMed ID: 7562757 [TBL] [Abstract][Full Text] [Related]
5. Establishment and partial validation of a patient skin self-assessment questionnaire in systemic sclerosis. Nagy Z; Bálint Z; Farkas H; Radics J; Kumánovics G; Minier T; Varjú C; Czirják L Rheumatology (Oxford); 2009 Mar; 48(3):309-14. PubMed ID: 19181657 [TBL] [Abstract][Full Text] [Related]
6. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694 [TBL] [Abstract][Full Text] [Related]
7. Is it possible to reduce observer variability in skin score assessment of scleroderma? The ad hoc International Group on the Assessment of Disease Outcome in Scleroderma. Silman A; Harrison M; Brennan P J Rheumatol; 1995 Jul; 22(7):1277-80. PubMed ID: 7562758 [TBL] [Abstract][Full Text] [Related]
8. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. Furst DE; Clements PJ; Steen VD; Medsger TA; Masi AT; D'Angelo WA; Lachenbruch PA; Grau RG; Seibold JR J Rheumatol; 1998 Jan; 25(1):84-8. PubMed ID: 9458208 [TBL] [Abstract][Full Text] [Related]
9. Healthy children have a significantly increased skin score assessed with the modified Rodnan skin score. Foeldvari I; Wierk A Rheumatology (Oxford); 2006 Jan; 45(1):76-8. PubMed ID: 16174648 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma. Low AHL; Ng SA; Berrocal V; Brennan B; Chan G; Ng SC; Khanna D Int J Rheum Dis; 2019 Jun; 22(6):1036-1040. PubMed ID: 30838791 [TBL] [Abstract][Full Text] [Related]
11. Quantification of hardness, elasticity and viscosity of the skin of patients with systemic sclerosis using a novel sensing device (Vesmeter): a proposal for a new outcome measurement procedure. Kuwahara Y; Shima Y; Shirayama D; Kawai M; Hagihara K; Hirano T; Arimitsu J; Ogata A; Tanaka T; Kawase I Rheumatology (Oxford); 2008 Jul; 47(7):1018-24. PubMed ID: 18440998 [TBL] [Abstract][Full Text] [Related]
12. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Czirják L; Nagy Z; Aringer M; Riemekasten G; Matucci-Cerinic M; Furst DE; Ann Rheum Dis; 2007 Jul; 66(7):966-9. PubMed ID: 17234649 [TBL] [Abstract][Full Text] [Related]
13. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Kissin EY; Merkel PA; Lafyatis R Arthritis Rheum; 2006 Nov; 54(11):3655-60. PubMed ID: 17075814 [TBL] [Abstract][Full Text] [Related]
14. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. DeMarco PJ; Weisman MH; Seibold JR; Furst DE; Wong WK; Hurwitz EL; Mayes M; White B; Wigley F; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241 [TBL] [Abstract][Full Text] [Related]
15. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Clements PJ; Hurwitz EL; Wong WK; Seibold JR; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen VD; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Furst DE Arthritis Rheum; 2000 Nov; 43(11):2445-54. PubMed ID: 11083267 [TBL] [Abstract][Full Text] [Related]
16. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register. Hanitsch LG; Burmester GR; Witt C; Hunzelmann N; Genth E; Krieg T; Lehmacher W; Melchers I; Meurer M; Müller-Ladner U; Schulze-Lohoff E; Becker M; Sunderkoetter C; ; Riemekasten G Rheumatology (Oxford); 2009 Jan; 48(1):70-3. PubMed ID: 19056798 [TBL] [Abstract][Full Text] [Related]
17. Associations of right ventricular myocardial function with skin and pulmonary involvement in asymptomatic patients with systemic sclerosis. D'Andrea A; Bellissimo S; Scotto di Uccio F; Vigorito F; Moscato F; Tozzi N; Di Donato M; Citro R; Stisi S; Scherillo M Ital Heart J; 2004 Nov; 5(11):831-9. PubMed ID: 15633438 [TBL] [Abstract][Full Text] [Related]
18. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460 [TBL] [Abstract][Full Text] [Related]
19. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Clements PJ; Furst DE; Wong WK; Mayes M; White B; Wigley F; Weisman MH; Barr W; Moreland LW; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold JR Arthritis Rheum; 1999 Jun; 42(6):1194-203. PubMed ID: 10366112 [TBL] [Abstract][Full Text] [Related]
20. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM; Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]